Ballicules.com

Brinzolamide

AZOPT

Pronunciation: brin-ZOE-la-mide

Brinzolamide ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Brinzolamide ballicule
Brinzolamide AZOPT mascot mnemonic cartoon
Visual mnemonic: Brinzolamide mascot
“Brian’s A zoo optometrist”

What it isTopical carbonic anhydrase inhibitor; open-angle glaucoma.

Why this oneA suspension rather than a solution, so it stings far less than dorzolamide, which improves adherence.

What limits itTransient blurred vision after instillation. It is a sulfonamide; corneal decompensation in a compromised endothelium.

Brinzolamide molecular structure (skeletal formula)
Molecular structure: Brinzolamide

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Elevated IOP in open-angle glaucoma or ocular hypertensionAdults1 drop TID1 drop TID

Renal Not recommended if CrCl <30 mL/min (severe impairment); not studied

Hepatic Undefined

Instructions

Available strengths

Cautions

Adverse reactions

Pregnancy No adequate human data; fetal toxicity in rats at high oral (systemic) doses

Lactation No human data; detected in milk of lactating rats

Cost

Brinzolamide (AZOPT)
Strength#/mogeneric $/unitCostPlus
1 %suspper unitnot offered
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Brinzolamide is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

Generic entry2020

NO BOXED WARNINGS

Principal riskTransient blurred vision; sulfonamide cross-reactivity

Classes and tags

Clinical profile

Therapeutic safety burden0 / 4
Overdose danger0 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk0 / 4

Legacy pregnancy categoryUnknown / historical label unavailable

Defining liabilityLocal irritation, sensitization or administration-site injury; negligible systemic toxicity at usual use.

Open Brinzolamide in the interactive console ↗